Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Cubist Pharms Drug Patent Portfolio

Cubist Pharms owns 1 orange book drug protected by 6 US patents Given below is the list of Cubist Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8112290 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug 31 Jul, 2030
Active
US8946262 Methods of preventing and treating gastrointestinal dysfunction 12 Feb, 2030
Active
US8645160 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug 18 Jun, 2029
Active
US6469030 Methods for the treatment and prevention of ileus 29 Nov, 2020 Expired
US5250542 Peripherally selective piperidine carboxylate opioid antagonists 29 Mar, 2016 Expired
US5434171 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates 08 Dec, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Cubist Pharms.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 13 Jul, 2023 US8112290
Payment of Maintenance Fee, 8th Year, Large Entity 16 Jul, 2019 US8112290
Change in Power of Attorney (May Include Associate POA)
Critical
13 Jul, 2016 US8112290
Email Notification
Critical
13 Jul, 2016 US8112290
Correspondence Address Change
Critical
12 Jul, 2016 US8112290
Email Notification
Critical
12 Apr, 2012 US8112290
Change in Power of Attorney (May Include Associate POA)
Critical
12 Apr, 2012 US8112290
Correspondence Address Change
Critical
06 Apr, 2012 US8112290
Recordation of Patent Grant Mailed
Critical
07 Feb, 2012 US8112290
Patent Issue Date Used in PTA Calculation
Critical
07 Feb, 2012 US8112290
Issue Notification Mailed
Critical
18 Jan, 2012 US8112290
Dispatch to FDC 04 Jan, 2012 US8112290
Application Is Considered Ready for Issue
Critical
04 Jan, 2012 US8112290
Issue Fee Payment Received
Critical
29 Dec, 2011 US8112290
Issue Fee Payment Verified
Critical
29 Dec, 2011 US8112290


Cubist Pharms's Family Patents

Cubist Pharms drugs have patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree.

Family Patents



Cubist Pharms Drug List

Given below is the complete list of Cubist Pharms's drugs and the patents protecting them.


1. Entereg

Entereg is protected by 6 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8112290 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug 31 Jul, 2030
(5 years from now)
Active
US8946262 Methods of preventing and treating gastrointestinal dysfunction 12 Feb, 2030
(5 years from now)
Active
US8645160 Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug 18 Jun, 2029
(4 years from now)
Active
US6469030 Methods for the treatment and prevention of ileus 29 Nov, 2020
(3 years ago)
Expired
US5250542 Peripherally selective piperidine carboxylate opioid antagonists 29 Mar, 2016
(8 years ago)
Expired
US5434171 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates 08 Dec, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entereg's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List